CNTX
Context Therapeutics Inc.·Healthcare
2.49
3.861%(−0.10)
Market ClosedLast Updated: — ET
52W L: $0.4952W H: $3.62
CNTX NEWS
globenewswire.com
Apr 2
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (“PROC”) in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers.
defenseworld.net
Mar 28
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating
defenseworld.net
Mar 27
Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)
Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Risk and Volatility Galectin Therapeutics has a
globenewswire.com
Mar 23
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. “We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors.
globenewswire.com
Mar 19
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company's asset, CT-202, a Nectin-4 x CD3 TCE.
defenseworld.net
Mar 10
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell engager (TCE) antibodies for solid tumors. Lehr described TCEs as antibodies that "bridge the gap" between immune T-cells and cancer cells by binding both
